226 related articles for article (PubMed ID: 35691122)
1. Sialylated glycoproteins as biomarkers and drivers of progression in prostate cancer.
Wen R; Zhao H; Zhang D; Chiu CL; Brooks JD
Carbohydr Res; 2022 Sep; 519():108598. PubMed ID: 35691122
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
[TBL] [Abstract][Full Text] [Related]
3. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
4. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
5. Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.
Gianchecchi E; Arena A; Fierabracci A
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071314
[TBL] [Abstract][Full Text] [Related]
6. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
Wieboldt R; Sandholzer M; Carlini E; Lin CW; Börsch A; Zingg A; Lardinois D; Herzig P; Don L; Zippelius A; Läubli H; Mantuano NR
Cell Mol Immunol; 2024 May; 21(5):495-509. PubMed ID: 38448555
[TBL] [Abstract][Full Text] [Related]
7. Siglec and anti-Siglec therapies.
Murugesan G; Weigle B; Crocker PR
Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
van Houtum EJH; Kers-Rebel ED; Looman MW; Hooijberg E; Büll C; Granado D; Cornelissen LAM; Adema GJ
Cell Mol Life Sci; 2023 May; 80(6):169. PubMed ID: 37253806
[TBL] [Abstract][Full Text] [Related]
9. Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.
Fan T; Liao Q; Zhao Y; Dai H; Song S; He T; Wang Z; Huang J; Zeng Z; Guo H; Zhang H; Qiu X
Cancer Sci; 2023 Feb; 114(2):370-383. PubMed ID: 36310398
[TBL] [Abstract][Full Text] [Related]
10. Tools to study and target the Siglec-sialic acid axis in cancer.
Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
[TBL] [Abstract][Full Text] [Related]
11. Sialylation pattern in lung epithelial cell line and Siglecs expression in monocytic THP-1 cells as cellular indicators of cigarette smoke - induced pathology in vitro.
Wielgat P; Trofimiuk E; Czarnomysy R; Holownia A; Braszko JJ
Exp Lung Res; 2018 Apr; 44(3):167-177. PubMed ID: 29781747
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions.
Boelaars K; Rodriguez E; Huinen ZR; Liu C; Wang D; Springer BO; Olesek K; Goossens-Kruijssen L; van Ee T; Lindijer D; Tak W; de Haas A; Wehry L; Nugteren-Boogaard JP; Mikula A; de Winde CM; Mebius RE; Tuveson DA; Giovannetti E; Bijlsma MF; Wuhrer M; van Vliet SJ; van Kooyk Y
Commun Biol; 2024 Apr; 7(1):430. PubMed ID: 38594506
[TBL] [Abstract][Full Text] [Related]
13. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9.
Rodriguez E; Boelaars K; Brown K; Eveline Li RJ; Kruijssen L; Bruijns SCM; van Ee T; Schetters STT; Crommentuijn MHW; van der Horst JC; van Grieken NCT; van Vliet SJ; Kazemier G; Giovannetti E; Garcia-Vallejo JJ; van Kooyk Y
Nat Commun; 2021 Feb; 12(1):1270. PubMed ID: 33627655
[TBL] [Abstract][Full Text] [Related]
14. Targeting sialylation to treat central nervous system diseases.
Lünemann JD; von Gunten S; Neumann H
Trends Pharmacol Sci; 2021 Dec; 42(12):998-1008. PubMed ID: 34607695
[TBL] [Abstract][Full Text] [Related]
15. Role of tumor cell sialylation in pancreatic cancer progression.
Marciel MP; Haldar B; Hwang J; Bhalerao N; Bellis SL
Adv Cancer Res; 2023; 157():123-155. PubMed ID: 36725107
[TBL] [Abstract][Full Text] [Related]
16. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
Boelaars K; van Kooyk Y
Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
[TBL] [Abstract][Full Text] [Related]
17. Recognition of sialylated meningococcal lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced bacterial uptake.
Jones C; Virji M; Crocker PR
Mol Microbiol; 2003 Sep; 49(5):1213-25. PubMed ID: 12940982
[TBL] [Abstract][Full Text] [Related]
18. Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway.
Grabenstein S; Barnard KN; Anim M; Armoo A; Weichert WS; Bertozzi CR; Parrish CR; Willand-Charnley R
Glycobiology; 2021 Nov; 31(10):1279-1294. PubMed ID: 34192335
[TBL] [Abstract][Full Text] [Related]
19. Lectin Affinity Chromatography for the Discovery of Novel Cancer Glycobiomarkers: A Case Study with PSA Glycoforms and Prostate Cancer.
Llop E; Peracaula R
Methods Mol Biol; 2022; 2370():301-313. PubMed ID: 34611876
[TBL] [Abstract][Full Text] [Related]
20. SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity.
Bouti P; Blans C; Klein BJAM; Shome D; Nadafi R; Van Houdt M; Schornagel K; Verkuijlen PJJH; Roos V; Reijmers RM; Van Bruggen R; Kuijpers TW; Matlung HL
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
